Liquid chromatographic method for the determination of rosiglitazone in human plasma

被引:52
作者
Kolte, BL
Raut, BB
Deo, AA
Bagool, MA
Shinde, DB [1 ]
机构
[1] Dr Babasaheb Ambedkar Marathwada Univ, Dept Chem Technol, Aurangabad 431004, Maharashtra, India
[2] Workhardt Res Ctr, Aurangabad, Maharashtra, India
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2003年 / 788卷 / 01期
关键词
rosiglitazone;
D O I
10.1016/S1570-0232(02)01011-5
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A robust, accurate and sensitive high-performance liquid chromatographic method for the determination of rosiglitazone (I) in human plasma has been developed. Pioglitazone (II) was used as internal standard. Both I and II are extracted from plasma using a liquid-liquid extraction procedure. Isocratic separation of I and II is carried out using a reversed-phase Zorbax SB C-18, 15-cm column with mobile phase consisting of methanol and a mixed phosphate buffer (10 mM monobasic sodium phosphate and dibasic sodium phosphate, pH adjusted to 2.6 with ortho-phosphoric acid) in the ratio 30:70 (v/v) and quantified by UV detection at 245 nm. Linearity was established over the range 5-1250 ng/ml using 1 ml human plasma. The method is specific, the endogenous components in plasma do not interfere with I and II. CV (%) of intra-day samples is less than 5.0% at four concentrations tested namely 5, 10, 500 and 1000 ng/ml. Similarly, over the same nominal concentrations, the precision of inter-day (5 days) samples also results in CV (%) less than 5.0%. The recoveries of I and II from human plasma were about 79 and 60%, respectively. This method can be used for routine clinical monitoring of I. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:37 / 44
页数:8
相关论文
共 11 条
[1]  
[Anonymous], 2001, Merck Index
[2]  
BOLTON S, 1997, PHARM STAT PRACTICAL, P239
[3]  
Cox PJ, 2000, DRUG METAB DISPOS, V28, P772
[4]   Systemic exposure to rosiglitazone is unaltered by food [J].
Freed, MI ;
Allen, A ;
Jorkasky, DK ;
DiCicco, RA .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (01) :53-56
[5]  
GAFFNEY MH, 1994, METHODOL SURV BIOANA, V23, P251
[6]   A HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE SIMULTANEOUS DETERMINATION OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE IN BIOLOGICAL-FLUIDS [J].
HICKS, DR ;
WOLANIUK, D ;
RUSSELL, A ;
CAVANAUGH, N ;
KRAML, M .
THERAPEUTIC DRUG MONITORING, 1994, 16 (01) :100-107
[7]  
KELLY GL, 2002, PDR, P1490
[8]   Effect of hepatic impairment on the pharmacokinetics (PK) of rosiglitazone (RSG). [J].
Miller, AK ;
Inglis, AL ;
Thompson, K ;
Davie, CC ;
Schenker, S ;
Blum, R ;
Jorkasky, D ;
Freed, MI .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) :186-186
[9]   Automated high-performance liquid chromatography method for the determination of rosiglitazone in human plasma [J].
Muxlow, AM ;
Fowles, S ;
Russell, P .
JOURNAL OF CHROMATOGRAPHY B, 2001, 752 (01) :77-84
[10]  
Patel J, 1998, DIABETES, V47, pA17